Tarsus Pharmaceuticals Inc (TARS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.88B
Last updated: Nov 17, 2026 at 4:20 PM ET
Tarsus Pharmaceuticals Inc (TARS) Statistics
Tarsus Pharmaceuticals (TARS) has a market cap of $3.88B and an enterprise value of $3.82B. It kept -102.93% of revenue as net income over the last 12 months. Revenue grew 86.34% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 1.64% below the market cap, as cash exceeds debt.
| Market Cap | $3.88B |
|---|---|
| Enterprise Value | $3.82B |
| Latest price (Nov 17, 2026) | $78.20 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.3x and 34.9x. Its year-end P/S ranged from 7.6x to 35.9x from 2021 to 2025.
| P/S Ratio | 5.3x |
|---|---|
| Forward P/S | 5.2x |
| P/B Ratio | 34.9x |
| P/TBV Ratio | 41.5x |
| P/FCF Ratio | 111.9x |
| P/OCF Ratio | 77.7x |
Enterprise Valuation
Counting debt and cash, the company is valued at 109.9x free cash flow.
| EV / Sales | 5.6x |
|---|---|
| EV / FCF | 109.9x |
Price Statistics
The stock is up 7.24% over 52 weeks and trades 5.08% above its 50-day average.
| Beta (1Y) | 0.60 |
|---|---|
| 52-Week Change | +7.24% |
| 1-Month Change | +12.52% |
| 3-Month Change | +6.48% |
| 6-Month Change | +27.59% |
| 5-Year Change | +169.63% |
| Total Return (1Y) | +7.24% |
| Total Return (3Y CAGR) | +60.64% |
| Total Return (5Y CAGR) | +25.49% |
| Return vs SPY (1Y) | -9.96% |
| Max Drawdown (1Y) | -32.00% |
| Max Drawdown (3Y) | -45.08% |
| Sharpe Ratio (1Y) | 0.04 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $74.42 |
| 200-Day Average | $68.10 |
| 52-Week Range | $53.89 to $91.53 |
| RSI (14 Days) | 59.6 |
| Average Volume (20 Days) | 849.95K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.96x current liabilities, and total debt is 0.70x shareholder equity.
| Current Ratio | 1.96x |
|---|---|
| Quick Ratio | 1.94x |
| Debt / Equity | 0.70x |
| Debt / FCF | 2.25x |
| Interest Coverage | -80.21x |
Returns and Efficiency
Return on invested capital is -393.56% over the last 12 months, against a 5-year average of -17.11%.
| Return on Equity (ROE) | -675.03% |
|---|---|
| Return on Assets (ROA) | -138.92% |
| Return on Invested Capital (ROIC) | -393.56% |
| ROE (5Y Average) | -36.05% |
| ROA (5Y Average) | -25.73% |
| ROIC (5Y Average) | -17.11% |
| Asset Turnover | 1.31x |
| Inventory Turnover | 9.72x |
| Receivables Turnover | 6.81x |
| Cash Conversion Cycle | -1314 days |
Scores
TARS has an Altman Z-Score of -0.36, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.36 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $682.20M over the last 12 months.
| Revenue | $682.20M |
|---|---|
| Revenue Growth (YoY) | +86.34% |
| Gross Profit | $635.87M |
| Operating Income | -$696.10M |
| Pretax Income | -$690.46M |
| Net Income | -$702.23M |
| Reported EPS (TTM) | -$1.57 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 20.58% of the $505.50M in total assets.
| Cash and Equivalents | $136.53M |
|---|---|
| Total Debt | $72.94M |
| Net Cash | $63.59M |
| Net Cash Per Share | $1.37 |
| Working Capital | $218.30M |
| Shareholder Equity | $104.03M |
| Book Value Per Share | $2.24 |
| Tangible Book Value | $87.38M |
| Tangible Book Per Share | $1.88 |
| Total Assets | $505.50M |
| Total Liabilities | $401.47M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $17.46M of capital spending, operating cash flow left $32.44M of free cash flow.
| Operating Cash Flow | $49.90M |
|---|---|
| Capital Expenditures | $17.46M |
| Free Cash Flow | $32.44M |
| FCF Per Share | $0.69 |
| Depreciation and Amortization | $3.31M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -102.04%.
| Gross Margin | 93.21% |
|---|---|
| Operating Margin | -102.04% |
| Pretax Margin | -101.21% |
| Net Margin | -102.93% |
| FCF Margin | 4.76% |
| Gross Margin (5Y Average) | 93.94% |
Growth
Revenue grew 159.54% a year over 3 years.
| Revenue Growth (3Y CAGR) | +159.54% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | +14.09% |
| Tangible Book Per Share Growth (2Y CAGR) | +13.98% |
Dividends and Yields
TARS does not pay a dividend. Its free cash flow yield is 0.89%.
| FCF Yield | 0.89% |
|---|---|
| Buyback Yield | -3.39% |
| Shareholder Yield | -3.39% |
Peer Position
Against 7 similar companies, TARS has the 4th highest P/S.
P/S RatioPeer median 5.2x
ROICPeer median -26.18%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -21.78%
| P/S Ratio | 5.3x vs 5.2x median |
|---|---|
| ROIC | -393.56% vs -26.18% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +86.34% vs -21.78% median |
Analyst Forecast
Consensus estimates put revenue growth at 43.96% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +43.96% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TARS
What is TARS's market cap?
Tarsus Pharmaceuticals has a market cap of $3.88B. Its enterprise value, which adds debt and subtracts cash, is $3.82B.
How many shares of TARS are outstanding?
Tarsus Pharmaceuticals has 46.42M shares outstanding. The count is up 8.95% from a year earlier.
Does TARS pay a dividend?
No. Tarsus Pharmaceuticals does not pay a dividend.
How much debt does TARS have?
Tarsus Pharmaceuticals has $72.94M of total debt and $136.53M of cash and equivalents, a net cash position of $63.59M.
TARS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors